| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01898377 Details | 2020-10-23 Interventional | 2 | 9 | Imatinib Mesyla… Mycophenolic Ac… Bronchiolitis O… Graft vs Host D… Chronic Graft-v… | New treatment option introduced for patients with the study indication - | |||
| NCT01897714 Details | 2020-10-23 Interventional | 1/2 | 75 | Dexamethasone Multiple Myelom… Neoplasms, Plas… Relapsed and/or… | The study was terminated at median 46-48 months long term follow-up and mature overall survival
follow-up data. Study is terminated and long-term follow-up ended due to Sponsor decision. | |||
| NCT00032773 Details | 2020-10-23 Interventional | 1/2 | - | Pentostatin Graft vs Host D… Acute Graft Ver… | - - | |||
| NCT03043651 Details | 2020-10-22 Interventional | 3 | 48 | Treprostinil Hypertension Hypertension, P… Pulmonary Hyper… | Terminated by Sponsor - | |||
| NCT02981459 Details | 2020-10-22 Interventional | 4 | 0 | Mirabegron Cystitis, Inter… Bladder Irritab… Bladder Pain Sy… Urinary Frequen… | Withdrawn by Sponsor - | |||
| NCT02953561 Details | 2020-10-22 Interventional | 1/2 | 19 | Antibodies, Mon… Avelumab Azacitidine Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Acute Myeloid L… Recurrent Acute… Refractory Acut… | PDOL request - | |||
| NCT02781805 Details | 2020-10-22 Interventional | 1 | 6 | Alendronate Breast Neoplasm… | - - | |||
| NCT02522975 Details | 2020-10-22 Interventional | 4 | 16 | Epoetin Alfa Anemia Renal Anaemia | - - | |||
| NCT02318368 Details | 2020-10-22 Interventional | 2 | 10 | Erlotinib Hydro… Carcinoma, Non-… Lung Neoplasms Non-small Cell … | Sponsor's decision The Sponsor terminated Study AV-299-14-206 before enrollment was completed, effective 14-Sep- 2016, after determining that enrollment of subjects was much lower than expected, and that timely completion of the study was not feasible. | |||
| NCT02032173 Details | 2020-10-22 Interventional | 3 | 31 | Ranibizumab Edema Macular Degener… Macular Edema Diabetes | Study was prematurely discontinued as it was unethical to continue based on a change in
ranibizumab (RFB) marketing authorization. - | |||
| NCT00328809 Details | 2020-10-22 Interventional | 4 | 0 | Spironolactone Heart Failure Kidney Diseases Kidney Failure,… Congestive Hear… End Stage Renal… | personnel shortage - | |||
| NCT03239860 Details | 2020-10-20 Interventional | 2 | 220 | Antibodies Antibodies, Mon… Multiple Sclero… Multiple Sclero… Sclerosis | Based on R&D strategic reasons, our co-development Partner financing the study disengaged from
the development of GNbAC1. - | |||
| NCT04516603 Details | 2020-10-19 Interventional | 2 | 0 | 4-Aminopyridine Working Memory | Changement of study design. Restart spring 2021. - | |||
| NCT03945227 Details | 2020-10-19 Interventional | 2 | 0 | Spartalizumab Carcinoma, Non-… Stage III NSCLC | Due to the delay in the study shceduled, due to the start of competitive study and the approval
of Durvalumab from the Ministry of Food and Drug Safety, it was judged that it was difficult to
enroll subjects. - | |||
| NCT03596723 Details | 2020-10-19 Interventional | 3 | 2 | Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Cataract Inflammation Ocular Inflamma… | NDA #210565 did not trigger the need for a Pediatric Research Equity Act study. Due to stopping the study after just two subjects were enrolled, no meaningful conclusions could be reached. | |||
| NCT02876094 Details | 2020-10-19 Interventional | 2 | 1 | Celecoxib Atrophy Muscular Atroph… Muscular Atroph… Spinal Muscular… | Terminated: Study halted prematurely and will not resume; participants are no longer being
examined or receiving intervention - | |||
| NCT02709889 Details | 2020-10-19 Interventional | 1/2 | 200 | Dexamethasone Rovalpituzumab … Carcinoma Carcinoma, Neur… Glioblastoma Melanoma High Grade Gast… Large-Cell Neur… Malignant Melan… Medullary Thyro… Neuroendocrine … Other Neuroendo… Other Solid Tum… | Strategic considerations - | |||
| NCT01806064 Details | 2020-10-19 Interventional | 1/2 | 173 | Axitinib Carcinoma Carcinoma, Rena… Renal Cell Carc… | The study did not meet endpoint. The study was terminated early due to lack of efficacy therefore protein biomarkers (P1b and P2), PK (P2), immunogenicity (P2) and disease control rate at 16 weeks by RECIST 1.1 and Choi criteria were not analyzed. | |||
| NCT01194960 Details | 2020-10-19 Interventional | 2 | [1 Refs] | 25 | Docetaxel Prostatic Neopl… Hormone Refract… | - - | ||
| NCT00622466 Details | 2020-10-19 Interventional | 2 | 20 | Paclitaxel Sorafenib Breast Neoplasm… Breast Cancer | Study sponsor requested that the study be permanently closed by letter. - |